Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Christophe Degois

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 01, 2024 11:02am

76 Views

Post# 36158265

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Christophe Degois

And Biden only returned a few hours beforehand, after crossing 7 times zones and back. We now know that. Now we know that he travelled to an unknown location to meet with Putin to negotiate the release of the 2 Americans jailed in Russia in the Biggest prisoner swap ( numbering 26 ) with the West since the Cold War - for 1 Russian

https://www.bbc.com/news/live/ck7gwe808yet

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing